|
Sign In to gain access to subscriptions and/or personal tools.
|
Beneficial Effect of Cholinesterase Inhibitor Medications on Recognition Memory Performance in Mild to Moderate Alzheimers Disease: Preliminary Findings
Timothy A. Crowell, PsyD
Roskamp Institute Memory Clinic, Tampa, Florida, TACrowell{at}excite.com
Juno Paramadevan, BA
Roskamp Institute Memory Clinic, Tampa, Florida
Laila Abdullah, BS
Roskamp Institute Memory Clinic, Tampa, Florida
Michael Mullan, MD, PhD
Roskamp Institute Memory Clinic, Tampa, Florida
Cholinesterase inhibitor (ChEI) medications (ie, donepezil, rivastigmine, and galantamine) have been useful in slowing the progression of the mild to moderate stages of Alzheimers disease (AD). Findings supporting this have largely relied on a global error score from the Alzheimers Disease Assessment Scale and have not described the nature of the memory problems. We examined this issue by comparing learning, recall, and recognition scores among 2 groups of mild to moderately demented AD patients. Participants were patients from a memory clinic who either were on ChEI treatment (AD+ChEI, n = 14) or had never taken a ChEI (AD-ChEI, n = 14). Participants underwent a comprehensive neuropsychological evaluation, including administration of the CERAD Word List Memory test. Results indicated no significant group difference for learning and delayed free recall, but the AD+ChEI group had significantly fewer errors than the AD-ChEI group on the CERAD Recognition test. Our findings provide preliminary evidence that the aspect of memory that is most affected by ChEIs appears to be facilitation of retention of new information in memory. The implications of this on clinical care and functional abilities as well as future directions are discussed.
Key Words: cholinesterase inhibitor dementia memory Alzheimers disease
References
- Ebert U, Kirch W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 1998;28:944-949.[CrossRef][Medline]
[Order article via Infotrieve]
- Hasselmo ME, Wyble BP. Free recall and recognition in a network model of the hippocampus: simulating effects of scopolamine on human memory function. Behav Brain Res 1997;89:1-34.[CrossRef][Medline]
[Order article via Infotrieve]
- Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimers diseaseresults from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-344.[CrossRef][Medline]
[Order article via Infotrieve]
- Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268.[Abstract/Free Full Text]
- Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimers disease: international randomised controlled trial. BMJ 1999;318:633-638.[Abstract/Free Full Text]
- McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 1984;34:939-944.[Abstract/Free Full Text]
- Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimers Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimers disease. Neurology 1989;39:1159-1165.[Abstract/Free Full Text]
Journal of Geriatric Psychiatry and Neurology, Vol. 19, No. 1,
13-15 (2006)
DOI: 10.1177/0891988705284711

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. Peters, F. Collette, C. Degueldre, V. Sterpenich, S. Majerus, and E. Salmon
The neural correlates of verbal short-term memory in Alzheimer's disease: an fMRI study
Brain,
July 1, 2009;
132(7):
1833 - 1846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ferrucci, F. Mameli, I. Guidi, S. Mrakic-Sposta, M. Vergari, S. Marceglia, F. Cogiamanian, S. Barbieri, E. Scarpini, and A. Priori
Transcranial direct current stimulation improves recognition memory in Alzheimer disease
Neurology,
August 12, 2008;
71(7):
493 - 498.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|